We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AB SCIEX Announces the 4500MD Series* for In Vitro Diagnostic Use
Product News

AB SCIEX Announces the 4500MD Series* for In Vitro Diagnostic Use

AB SCIEX Announces the 4500MD Series* for In Vitro Diagnostic Use
Product News

AB SCIEX Announces the 4500MD Series* for In Vitro Diagnostic Use


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AB SCIEX Announces the 4500MD Series* for In Vitro Diagnostic Use"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AB SCIEX today confirmed its commitment to support the diagnostic market with the unveiling of the Triple Quad™ 4500MD and QTRAP® 4500MD LC/MS/MS systems under its SCIEX Diagnostics brand. Expected to be available in the US and select EU countries in September, the 4500MD series joins the company’s growing family of in vitro diagnostic devices, including the 3200MD*, and IVD-MS™ Analyzer* systems launched in 2013, as well as a series of kits* for vitamin D, immunosuppressants and newborn screening testing to be available in August 2014 for use in certain European countries.
   
The new 4500MD series offers exceptional sensitivity and faster data acquisition over previous systems allowing clinical customers to obtain reliable results so physicians and patients have accurate answers quickly.
 
The 4500MD series is a flexible LC/MS/MS platform that offers enhanced performance, improved sensitivity and faster data acquisition, to enable customers developing their own applications to validate methods that require lower detection limits or higher throughput, with the peace of mind afforded by a regulatory compliant solution.
 
“As scientific understanding progressively evolves into improved clinical diagnostic testing, diagnostic customers who develop their own assays are turning to fast, sensitive instruments to perform routine tests with high efficiency and cost savings,” said Chris Radloff, Vice President, Applied Markets and Clinical Research at AB SCIEX. “By bringing the power, flexibility, reliability, and accuracy of our mass spectrometry technology to clinical testing laboratories, AB SCIEX is enabling customers to deliver high quality diagnostic information to clinicians who make decisions affecting patient care.”
 
SCIEX Diagnostics is focused on delivering high quality technology, service and support to the clinical diagnostics market and is part of AB SCIEX. Throughout the week at the 2014 AACC Annual Meeting, SCIEX Diagnostics will unveil its latest product at booth #3418. Follow AB SCIEX at AACC on Twitter with hashtag #ABSCIEXWORLD and #aacc2014.

Advertisement